3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
3
Glioma
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Astrocytoma
1
Advanced Cancer
1
Interventions
Temozolomide
29
Bevacizumab
15
Radiotherapy
13
antineoplaston AS 2-1
8
antineoplaston A10
8
Everolimus
7
Radiation
6
Erlotinib Hydrochloride
6
Radiotherapy, Intensity-Modulated
5
Lomustine
4
veliparib
3
palbociclib
3
Vorinostat
3
Sunitinib
3
Radiotherapy, Conformal
3
Magnetic Resonance Spectroscopy
3
Carmustine
3
Carboplatin
3
temsirolimus
2
selinexor
2
poly ICLC
2
etoposide phosphate
2
cabozantinib
2
Sirolimus
2
Nivolumab
2
Irinotecan
2
Immunoglobulin G
2
Imatinib Mesylate
2
Etoposide
2
Donepezil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Astrocytoma
×
Tetanus Toxoid
×
Clear all
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts